Whitehawk Therapeutics Appoints Director Vijay Iyengar

What Happened

• Whitehawk Therapeutics (WHWK) increased its board size from nine to ten and appointed Vijay Iyengar, M.D., as a Class III director effective September 9, 2026. Dr. Iyengar’s term runs until the Company’s 2029 annual meeting of stockholders, subject to earlier resignation, death or removal.
• Dr. Iyengar, age 54, has held senior roles in the biopharma industry, including Executive Vice President, Global Medical Affairs, Product and Partnership Strategy at Incyte (May 2022–Nov 2025) and prior leadership positions at Incyte, Genoptix (a Novartis company) and Novartis. He holds a B.S. from Stanford and an M.D. from Harvard Medical School.

Key Details

• Board change: increased authorized directors from 9 to 10 and filled the new seat on Sept 9, 2026.
• Compensation: as a non-employee director, Dr. Iyengar will participate in the Company’s Outside Director Compensation Policy (base annual retainer of $40,000).
• Equity award: initial grant of options to purchase 76,080 shares, granted on September 9, 2026, vesting monthly over three years, subject to continued service.
• Governance: Company entered into its standard indemnification agreement with Dr. Iyengar; no family relationships or related‑party transactions reported.

Why It Matters

• The appointment adds experienced industry and medical leadership to Whitehawk’s board, which may strengthen oversight on clinical, medical affairs and strategy matters.
• The equity grant and standard retainer are routine for non‑employee directors but will modestly increase potential share-based dilution over time as options vest.
• For investors, this is a governance update rather than an operational or financial change—watch for any future commentary from the Company on strategic or clinical impacts tied to the new director.